A study testing doses of BI 764532 in people with a DLL3 positive brain tumor
Original title: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people to find a dose they can tolerate.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing how much of a drug called BI 764532 people with a brain tumor can handle.
Who this trial is for. This study is for adults with a tumor in the brain that is positive for a marker called DLL3, and who have advanced cancer that did not respond to earlier treatment. It is testing the highest dose of BI 764532 that people can tolerate. BI 764532 is an antibody-like molecule that links cancer cells to T cells of the immune system, which may help the immune system fight cancer.
Where it stands. The study is measuring how well people tolerate the drug at different doses. People get the drug as infusions into a vein and visit the study site at set times. Doctors record any unwanted effects and check people's general health. The study has not reported results.
What this means, and what it doesn't
What it could mean: If you have a brain tumor that is positive for DLL3 and past treatment has not worked, this is one study you could ask your care team about. They can tell you if it makes sense to look into it. The study team decides who can join.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Joining a study is not a guarantee that you will be helped, and it is not a promise of a cure. Doses are still being tested, so the safe amount is not known yet.
Source: ClinicalTrials.gov, August 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.